SXTC (China SXT Pharmaceuticals) Long-Term Debt: $0.64 Mil (As of Mar. 2026)


SXTC China SXT Pharmaceuticals Inc SXTC
48 GF Score
Price $2.56
GF Value $2.05
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals Long-Term Debt?

China SXT Pharmaceuticals SXTC +0.79% 48 Long-Term Debt is $0.64 Mil as of Mar. 2026. GuruFocus rates SXTC with a GF Score™ of 48/100 and a GF Value™ of $2.05 (Modestly Overvalued). The stock has 7 warning signs investors should review.

China SXT Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.64 Mil.

China SXT Pharmaceuticals's quarterly Long-Term Debt declined from Mar. 2025 ($0.10 Mil) to Sep. 2025 ($0.07 Mil) but then increased from Sep. 2025 ($0.07 Mil) to Mar. 2026 ($0.64 Mil).

China SXT Pharmaceuticals's annual Long-Term Debt declined from Mar. 2024 ($0.12 Mil) to Mar. 2025 ($0.10 Mil) but then increased from Mar. 2025 ($0.10 Mil) to Mar. 2026 ($0.64 Mil).

China SXT Pharmaceuticals  (NAS:SXTC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

China SXT Pharmaceuticals Long-Term Debt Related Terms

China SXT Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals Long-Term Debt Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.12 0.12 0.10 0.64

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.00 0.10 0.07 0.64
SXTC
48GF Score
China SXT Pharmaceuticals Inc SXTC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.64 Mil mean?
China SXT Pharmaceuticals (SXTC) has a Long-Term Debt of $0.64 Mil as of Mar. 2026.
Is China SXT Pharmaceuticals' Long-Term Debt too high?
China SXT Pharmaceuticals' current Long-Term Debt is $0.64 Mil. Overall, China SXT Pharmaceuticals has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Long-Term Debt compare to CABR and BFRI?
China SXT Pharmaceuticals' Long-Term Debt of $0.64 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. China SXT Pharmaceuticals's current Long-Term Debt is $0.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (SXTC) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $2.56 — trading 24.9% above its estimated fair value. The current Long-Term Debt is $0.64 Mil. China SXT Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current Long-Term Debt is $0.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (SXTC) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be overvalued. The current stock price of $2.56 is trading 24.9% above its estimated GF Value™ of $2.05. GuruFocus considers China SXT Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for SXTC:

  • Long-Term Debt: $0.64 Mil
  • GF Value™: $2.05 vs. price of $2.56 (24.9% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the SXTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
48GF Score

Get the complete analysis for SXTC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price
$2.05
GF Value